Intuitive Surgical Surpasses Q1 Earnings Expectations, Shares Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ISRG?
Source: Fool
- Significant Earnings Growth: Intuitive Surgical's Q1 sales and adjusted EPS increased by 23% and 38%, respectively, exceeding Wall Street expectations and driving an 8% rise in stock price.
- Procedure Volume Increase: Total procedures grew by 17%, with Ion procedures (bronchoscopies for early lung cancer detection) surging by 39%, showcasing the company's robust performance in the medical field.
- International Market Expansion: Da Vinci procedures outside the U.S. grew by 19%, now accounting for 38% of total volume, fueled by reimbursement policy changes in Japan and Europe, further driving global expansion.
- Innovation-Driven Growth: The company received FDA 510(k) clearance for its Force Feedback instruments, now cleared for 15 uses, demonstrating ongoing innovation that enhances surgical outcomes and solidifies its market leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 470.990
Low
575.00
Averages
637.32
High
740.00
Current: 470.990
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insider at Intuitive Surgical (ISRG.US) Plans to Sell $14.32 Million in Common Stock via Form 144
Share Sale Announcement: McAdams Family Revocable Living Trust plans to sell 30,417 shares of Intuitive Surgical stock on April 27, with a total market value of approximately $14.32 million.
Reduction in Holdings: The McAdams Family Revocable Living Trust has reduced its holdings in Intuitive Surgical by 8,185 shares since January 27, 2026, with a total value of around $4.04 million.
See More
BARCLAYS LOWERS INTUITIVE SURGICAL TARGET PRICE TO $651, DOWN FROM $712
- Intuitive Surgical's Stock Target: Barclays has reduced the target price for Intuitive Surgical's stock from $712 to $651.
- Market Impact: This adjustment reflects Barclays' updated outlook on the company's performance and market conditions.
See More
Three Healthcare Stocks with Durable Competitive Moats
- Eli Lilly's Market Edge: Eli Lilly (LLY) solidifies its market share with popular weight loss drugs like Mounjaro and Zepbound, while the recent approval of the oral weight loss drug Foundayo is expected to drive future earnings growth.
- Vertex Pharmaceuticals' Patent Protection: Vertex Pharmaceuticals (VRTX) leads globally in cystic fibrosis drugs, with patent protection extending into the late 2030s, and ongoing innovation positions it for strong profitability and potential new product launches.
- Intuitive Surgical's Robotic Surgery Dominance: Intuitive Surgical (ISRG) maintains a dominant position with its Da Vinci surgical robots, as hospitals investing in these high-cost devices are likely to continue using them, reinforcing its market position.
- Training Advantage in the Industry: Most surgeons are trained on the Da Vinci system, creating a familiarity that leads hospitals to prefer this platform, thereby strengthening Intuitive Surgical's competitive moat.
See More
Company Moats Support Earnings Growth
- Importance of Moats: Company moats, such as brand strength and patent portfolios, help firms maintain competitive advantages, thereby supporting future earnings growth and attracting investor interest.
- Eli Lilly's Competitive Edge: Eli Lilly's weight loss drugs like Mounjaro and Zepbound benefit from strong physician trust and patient satisfaction, creating a robust market moat, with patent protection extending to 2036, ensuring long-term profitability.
- Vertex Pharmaceuticals' Innovation: Vertex Pharmaceuticals leads in cystic fibrosis drugs, with patent protection lasting into the late 2030s, and its collaboration with Moderna on mRNA therapies could further solidify its market position, potentially treating the entire CF population.
- Intuitive Surgical's Market Leadership: Intuitive Surgical's Da Vinci surgical robots create a solid moat due to high investment costs and surgeon familiarity, driving continuous growth and ensuring its leading position in the healthcare industry.
See More
Aging Population Boosts Healthcare Tech Growth
- Market Opportunity: The accelerating global aging population is projected to reach 1.4 billion people aged 65 and older by 2030, driving demand for healthcare technology, particularly in telemedicine and health monitoring sectors.
- Technological Innovation: Healthcare technology companies are increasing investments in artificial intelligence and big data analytics to enhance patient care quality and operational efficiency, thereby gaining a competitive edge in a crowded market.
- Policy Support: Governments worldwide are implementing policies to encourage healthcare technology innovation and investment, which is expected to bring billions of dollars into the industry, further promoting market expansion.
- Investment Outlook: As the aging population grows, the attractiveness of investments in the healthcare technology sector continues to rise, with significant increases in market valuations for related companies anticipated over the next five years, drawing more investor attention.
See More
Intuitive Surgical's Growth Potential in Surgical Robotics Market
- Market Share Growth: By the end of 2025, Intuitive Surgical's installed base of da Vinci surgical robots exceeded 11,100 units, reflecting a 12% year-over-year growth that underscores the company's strong demand and expansion potential in the surgical robotics market.
- Significant Revenue Growth: In Q4 2025, Intuitive Surgical reported a 19% year-over-year revenue increase, with adjusted earnings per share rising from $2.21 in 2024 to $2.53, indicating the company's robust performance in the rapidly growing medical technology sector.
- Service Revenue Dominance: Approximately 75% of the company's revenue comes from services, instruments, and accessories, which grow as the installed base of da Vinci systems increases, demonstrating the sustainability and stability of its business model.
- Rising Surgical Demand: In 2025, the growth rate of surgeries performed using da Vinci robots reached 18%, significantly outpacing the 12% sales growth, indicating that the application of surgical robotics in the healthcare industry is expanding, driving future growth for the company.
See More
Insider at Intuitive Surgical (ISRG.US) Plans to Sell $14.32 Million in Common Stock via Form 144
Share Sale Announcement: McAdams Family Revocable Living Trust plans to sell 30,417 shares of Intuitive Surgical stock on April 27, with a total market value of approximately $14.32 million.
Reduction in Holdings: The McAdams Family Revocable Living Trust has reduced its holdings in Intuitive Surgical by 8,185 shares since January 27, 2026, with a total value of around $4.04 million.
See More
BARCLAYS LOWERS INTUITIVE SURGICAL TARGET PRICE TO $651, DOWN FROM $712
- Intuitive Surgical's Stock Target: Barclays has reduced the target price for Intuitive Surgical's stock from $712 to $651.
- Market Impact: This adjustment reflects Barclays' updated outlook on the company's performance and market conditions.
See More
Three Healthcare Stocks with Durable Competitive Moats
- Eli Lilly's Market Edge: Eli Lilly (LLY) solidifies its market share with popular weight loss drugs like Mounjaro and Zepbound, while the recent approval of the oral weight loss drug Foundayo is expected to drive future earnings growth.
- Vertex Pharmaceuticals' Patent Protection: Vertex Pharmaceuticals (VRTX) leads globally in cystic fibrosis drugs, with patent protection extending into the late 2030s, and ongoing innovation positions it for strong profitability and potential new product launches.
- Intuitive Surgical's Robotic Surgery Dominance: Intuitive Surgical (ISRG) maintains a dominant position with its Da Vinci surgical robots, as hospitals investing in these high-cost devices are likely to continue using them, reinforcing its market position.
- Training Advantage in the Industry: Most surgeons are trained on the Da Vinci system, creating a familiarity that leads hospitals to prefer this platform, thereby strengthening Intuitive Surgical's competitive moat.
See More
Company Moats Support Earnings Growth
- Importance of Moats: Company moats, such as brand strength and patent portfolios, help firms maintain competitive advantages, thereby supporting future earnings growth and attracting investor interest.
- Eli Lilly's Competitive Edge: Eli Lilly's weight loss drugs like Mounjaro and Zepbound benefit from strong physician trust and patient satisfaction, creating a robust market moat, with patent protection extending to 2036, ensuring long-term profitability.
- Vertex Pharmaceuticals' Innovation: Vertex Pharmaceuticals leads in cystic fibrosis drugs, with patent protection lasting into the late 2030s, and its collaboration with Moderna on mRNA therapies could further solidify its market position, potentially treating the entire CF population.
- Intuitive Surgical's Market Leadership: Intuitive Surgical's Da Vinci surgical robots create a solid moat due to high investment costs and surgeon familiarity, driving continuous growth and ensuring its leading position in the healthcare industry.
See More
Aging Population Boosts Healthcare Tech Growth
- Market Opportunity: The accelerating global aging population is projected to reach 1.4 billion people aged 65 and older by 2030, driving demand for healthcare technology, particularly in telemedicine and health monitoring sectors.
- Technological Innovation: Healthcare technology companies are increasing investments in artificial intelligence and big data analytics to enhance patient care quality and operational efficiency, thereby gaining a competitive edge in a crowded market.
- Policy Support: Governments worldwide are implementing policies to encourage healthcare technology innovation and investment, which is expected to bring billions of dollars into the industry, further promoting market expansion.
- Investment Outlook: As the aging population grows, the attractiveness of investments in the healthcare technology sector continues to rise, with significant increases in market valuations for related companies anticipated over the next five years, drawing more investor attention.
See More
Intuitive Surgical's Growth Potential in Surgical Robotics Market
- Market Share Growth: By the end of 2025, Intuitive Surgical's installed base of da Vinci surgical robots exceeded 11,100 units, reflecting a 12% year-over-year growth that underscores the company's strong demand and expansion potential in the surgical robotics market.
- Significant Revenue Growth: In Q4 2025, Intuitive Surgical reported a 19% year-over-year revenue increase, with adjusted earnings per share rising from $2.21 in 2024 to $2.53, indicating the company's robust performance in the rapidly growing medical technology sector.
- Service Revenue Dominance: Approximately 75% of the company's revenue comes from services, instruments, and accessories, which grow as the installed base of da Vinci systems increases, demonstrating the sustainability and stability of its business model.
- Rising Surgical Demand: In 2025, the growth rate of surgeries performed using da Vinci robots reached 18%, significantly outpacing the 12% sales growth, indicating that the application of surgical robotics in the healthcare industry is expanding, driving future growth for the company.
See More
